Passez à l'illimité avec Magzter GOLD
Obtenez un accès illimité à plus de 9 000 magazines, journaux et articles Premium pour seulement
Essayer OR - Gratuit
Does US cancer drug nod make Cipla attractive?
Mint Mumbai
|April 18, 2025
Cipla, which makes HIV, respiratory and cancer drugs, is targeting North America with generic launches
Cipla Ltd's shares have surged 6% since last week when it announced the final approval from the US Food and Drug Administration for its generic version of Bristol Myers Squibb's Abraxane, a cancer drug. Does the approval to sell the much-awaited product in the US make Cipla a compelling buy, especially when Trump's tariffs loom?
"One product approval by itself doesn't suddenly make a company more attractive," said Prashant Nair, lead analyst for pharma and healthcare at Ambit Capital. "Earlier-than-expected approval for Abraxane is positive, but tariffs will have a bearing on Cipla."
Cette histoire est tirée de l'édition April 18, 2025 de Mint Mumbai.
Abonnez-vous à Magzter GOLD pour accéder à des milliers d'histoires premium sélectionnées et à plus de 9 000 magazines et journaux.
Déjà abonné ? Se connecter
PLUS D'HISTOIRES DE Mint Mumbai
Mint Mumbai
H-1B row, tariffs, FPI exit may sting rupee
Trump hit on remittances, exports; FPI selloff adds to pressure
2 mins
September 29, 2025
Mint Mumbai
Fabindia sued by subsidiary founders over exit clause
The co-founders of Fabindia Ltd’s personal care subsidiary, Biome Life Sciences India Pvt. Ltd, have sued the apparel retailer in the Delhi high court, seeking to enforce an exit clause they say value their shares at ₹196.16 crore.
3 mins
September 29, 2025
Mint Mumbai
US senators mount scrutiny on IT cos
Even as US president Donald Trump's steep hike in H-1B visa fee threatens to hit Indian software services providers, US lawmakers and agencies have separately intensified scrutiny of the offshoring sector.
3 mins
September 29, 2025
Mint Mumbai
The slow demise of Russian oil
Russia has powered its war in Ukraine by keeping its oil flowing. Now, after more than 3 years of conflict, the gusher is slowly starting to peter out.
3 mins
September 29, 2025
Mint Mumbai
Does Connected TV love advertisers back?
As chasing eyeballs on social media becomes expensive with diminishing returns, advertisers are pouring ad money into connected TVs
4 mins
September 29, 2025
Mint Mumbai
India has a viable voyage plan to acquire self-reliance in shipping
Four major moves have been made to achieve the PM’s goal of a 30% share in global maritime trade
3 mins
September 29, 2025
Mint Mumbai
EM private credit flows on course for a record year
Emerging markets are on a tear this year and that is drawing some of the hottest names in finance—lenders from the private credit world.
1 min
September 29, 2025
Mint Mumbai
Lens on challenges at Tata Play as CEO's exit looms
Tata Play Ltd's longtime chief executive Harit Nagpal will step down in late 2026, closing a 15-year run that turned the broadcaster into India’s largest direct-to-home (DTH) provider, but leaving his successor to navigate an industry grappling with a shrinking pay-TV market, subscriber losses, intensifying over-the-top (OTT) competition and rising fibre-to-home alternatives.
1 mins
September 29, 2025
Mint Mumbai
Hedge-fund stars are making so much now that they are hiring agents
Top hedge-fund recruits are getting hounded with job offers that would pay them like Hollywood stars or pro athletes. So why don’t they also have agents representing them?
4 mins
September 29, 2025
Mint Mumbai
Reliance Retail gets relief from NCLAT
A relief to Reliance Retail Ltd, appellate tribunal NCLAT has set aside a petition against the retailer, which in 2023 reduced the equity share capital of the firm, saying non-promoters were offered a “fair value” of their shares.
1 min
September 29, 2025
Listen
Translate
Change font size